Copycat Weight-Loss Pill Removed From the Market Amid FDA Crackdown

(MedPage Today) — The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the market…

Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/119806

Author :

Publish date : 2026-02-09 20:19:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Copycat Weight-Loss Pill Removed From the Market Amid FDA Crackdown

Non-Sterile Wipes Tied to Fatal Infection, Officials Say

Nurses Say They Might Return to Hospitals If Employers Made These Changes

Related Posts

Inflammation May Explain Link Between Belly Fat, HF

Are humans degenerating genetically and getting dumber as a result?

Arterial Stiffness Changes Linked to Developing Dementia

UK’s transplant system was world-leading – now it lags behind other Western nations

Cuba’s mothers-to-be prepare to give birth in a country plunged into darkness

Floaters May Signal Urgent Need for Specialty Attention

Inflammation May Explain Link Between Belly Fat, HF

Are humans degenerating genetically and getting dumber as a result?

Arterial Stiffness Changes Linked to Developing Dementia

UK’s transplant system was world-leading – now it lags behind other Western nations

Cuba’s mothers-to-be prepare to give birth in a country plunged into darkness

Floaters May Signal Urgent Need for Specialty Attention

‘The 1980s Called’: CMS Rule Aims to Phase Out Fax Machines for Health Claims

Brain Waves During Sleep Predict Dementia Risk

Categories

Archives